Madrigal Pharmaceuticals, Inc. $MDGL is University of Wisconsin Foundation's 3rd Largest Position

Key Points

• The University of Wisconsin Foundation increased its holdings in Madrigal Pharmaceuticals by 16.5%, making it the foundation's third largest position, representing 12.4% of its total portfolio.
• Madrigal Pharmaceuticals reported an EPS of ($1.90) for the last quarter, outperforming analysts' expectations and showing significant year-over-year revenue growth of 1357.5%.
• Several equity analysts have issued "buy" ratings for Madrigal Pharmaceuticals, with price targets reflecting expectations of significant price appreciation, the highest being up to $523.00.

University of Wisconsin Foundation grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 16.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,376 shares of the biopharmaceutical company's stock after purchasing an additional 6,835 shares during the period. Madrigal Pharmaceuticals makes up 12.4% of University of Wisconsin Foundation's portfolio, making the stock its 3rd biggest position. University of Wisconsin Foundation owned about 0.22% of Madrigal Pharmaceuticals worth $16,024,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of MDGL. VSM Wealth Advisory LLC purchased a new stake in shares of Madrigal Pharmaceuticals in the first quarter valued at $25,000. Accent Capital Management LLC acquired a new position in shares of Madrigal Pharmaceuticals in the first quarter worth $25,000. Summit Securities Group LLC acquired a new position in shares of Madrigal Pharmaceuticals in the first quarter worth $33,000. Farther Finance Advisors LLC increased its stake in shares of Madrigal Pharmaceuticals by 825.0% in the first quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 99 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Madrigal Pharmaceuticals by 131.4% in the first quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.

Madrigal Pharmaceuticals Trading Up 1.9%

Madrigal Pharmaceuticals stock opened at $414.68 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.11 and a quick ratio of 4.78. The company has a market capitalization of $9.21 billion, a price-to-earnings ratio of -32.27 and a beta of -1.02. Madrigal Pharmaceuticals, Inc. has a one year low of $200.63 and a one year high of $419.99. The company's fifty day moving average price is $321.05 and its two-hundred day moving average price is $316.59.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, topping the consensus estimate of ($3.48) by $1.58. The firm had revenue of $212.80 million for the quarter, compared to the consensus estimate of $158.94 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The business's quarterly revenue was up 1357.5% on a year-over-year basis. During the same period in the prior year, the business posted ($7.10) earnings per share. On average, analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Insider Activity

In other Madrigal Pharmaceuticals news, CEO William John Sibold sold 7,616 shares of the stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $400.18, for a total transaction of $3,047,770.88. Following the transaction, the chief executive officer directly owned 109,753 shares of the company's stock, valued at $43,920,955.54. This represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kenneth Bate sold 10,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $365.20, for a total transaction of $3,652,000.00. Following the transaction, the director directly owned 2,627 shares in the company, valued at $959,380.40. The trade was a 79.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders acquired 165,683 shares of company stock valued at $61,921,142 and sold 301,740 shares valued at $109,461,331. Corporate insiders own 21.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on MDGL shares. JMP Securities upped their price target on shares of Madrigal Pharmaceuticals from $483.00 to $485.00 and gave the stock a "market outperform" rating in a research note on Wednesday. Wall Street Zen raised shares of Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, May 5th. UBS Group reaffirmed a "buy" rating and issued a $523.00 price target (up from $458.00) on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 12th. Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Finally, B. Riley reaffirmed a "buy" rating and issued a $460.00 price target (up from $422.00) on shares of Madrigal Pharmaceuticals in a research note on Friday, May 2nd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Madrigal Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $445.71.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.